{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:18:51Z","timestamp":1779175131011,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Foamix Pharmaceuticals","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00520-018-4600-8","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T19:28:18Z","timestamp":1546543698000},"page":"3027-3033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study"],"prefix":"10.1007","volume":"27","author":[{"given":"Einat","family":"Shacham Shmueli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravit","family":"Geva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirit","family":"Yarom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayala","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Keynan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal H.","family":"Kedem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Eini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dov","family":"Tamarkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Shirvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"key":"4600_CR1","doi-asserted-by":"publisher","first-page":"734249","DOI":"10.1155\/2014\/734249","volume":"2014","author":"K Chanprapaph","year":"2014","unstructured":"Chanprapaph K, Vachiramon V, Rattanakaemakorn P (2014) Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract 2014:734249. \n                    https:\/\/doi.org\/10.1155\/2014\/734249","journal-title":"Dermatol Res Pract"},{"key":"4600_CR2","unstructured":"Erbitux (cetuximab) Prescribing Information. Indianapolis, IN: Eli Lilly and Company; October 2016"},{"key":"4600_CR3","unstructured":"Vectibix (panitumumab) Prescribing Information. 2015. Thousand Oaks, CA: Amgen, Inc; March 2015"},{"issue":"3","key":"4600_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/ijd.12205","volume":"53","author":"JL Curry","year":"2014","unstructured":"Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG (2014) Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 53(3):376\u2013384. \n                    https:\/\/doi.org\/10.1111\/ijd.12205","journal-title":"Int J Dermatol"},{"issue":"11 Suppl 5","key":"4600_CR5","first-page":"34","volume":"21","author":"LI Wagner","year":"2007","unstructured":"Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21(11 Suppl 5):34\u201336","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"4600_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.12788\/jcso.0193","volume":"14","author":"J Brown","year":"2016","unstructured":"Brown J, Su Y, Nelleson D, Shankar P, Mayo C (2016) Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review. J Community Support Oncol 14(1):21\u201328. \n                    https:\/\/doi.org\/10.12788\/jcso.0193","journal-title":"J Community Support Oncol"},{"issue":"12","key":"4600_CR7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40265-015-0434-6","volume":"75","author":"R Califano","year":"2015","unstructured":"Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, Thomas A, Thatcher N, Nicolson M (2015) Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs 75(12):1335\u20131348. \n                    https:\/\/doi.org\/10.1007\/s40265-015-0434-6","journal-title":"Drugs"},{"issue":"8","key":"4600_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA, Group MSTS (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079\u20131095. \n                    https:\/\/doi.org\/10.1007\/s00520-011-1197-6","journal-title":"Support Care Cancer"},{"issue":"8","key":"4600_CR9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351\u20131357. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.21.7828","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"4600_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/ajco.12160","volume":"10","author":"R Sinclair","year":"2014","unstructured":"Sinclair R (2014) Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors. Asia Pac J Clin Oncol 10(Suppl 1):11\u201317. \n                    https:\/\/doi.org\/10.1111\/ajco.12160","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"4600_CR11","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ (2005) Safety of doxycycline and minocycline: a systematic review. Clin Ther 27(9):1329\u20131342. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2005.09.005","journal-title":"Clin Ther"},{"issue":"4","key":"4600_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","volume":"61","author":"A Scope","year":"2009","unstructured":"Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC (2009) A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61(4):614\u2013620. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2009.03.046","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4600_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","volume":"18","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509\u2013522. \n                    https:\/\/doi.org\/10.1007\/s00520-009-0744-x","journal-title":"Support Care Cancer"},{"issue":"6","key":"4600_CR14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/bjd.14756","volume":"175","author":"F Petrelli","year":"2016","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, Barni S (2016) Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol 175(6):1166\u20131174. \n                    https:\/\/doi.org\/10.1111\/bjd.14756","journal-title":"Br J Dermatol"},{"issue":"3\u20134","key":"4600_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"SL Boone","year":"2007","unstructured":"Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3\u20134):152\u2013159. \n                    https:\/\/doi.org\/10.1159\/000112795","journal-title":"Oncology"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4600-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T19:05:06Z","timestamp":1578078306000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4600-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4600"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4600-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,4]]},"assertion":[{"value":"4 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was supported by Foamix Pharmaceuticals. Einat Shacham Shmueli served as principal investigator on this study and has received a grant from Foamix Pharmaceuticals. Ravit Geva, Nirit Yarom, and Ayala Hubert served as investigators on this study. Rita Keynan, Tal Hetzroni Kedem, Dov Tarmakin, and Mitchell Shirvan are employees of Foamix Pharmaceuticals. Meir Eini serves as a consultant for Foamix Pharmaceuticals. Mitchell Shirvan, Tal Hetzroni, and Meir Eini receive stock options from Foamix Pharmaceuticals. Ravit Geva reports other from MSD, Novartis, BMS, Roche, Janssen, Takeda, Medison, Merck, and Pfizer, outside the submitted work. The authors state that they have full control of all primary data, and they agree to allow the journal to review their data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}